Syntropic Medical

Syntropic Medical operates at the intersection of medical devices, neuromodulation, neuroscience, and digital mental health. Its differentiation is a non-invasive, headset-based approach intended to stimulate neuroplasticity through 60 Hz visual neuromodulation, rather than relying on a conventional pharmaceutical antidepressant mechanism. The company describes Haven™ as a medical headset for Major Depressive Disorder and cites 70% remission in two weeks, although the underlying study design, cohort size, comparator, and regulatory status are not detailed in the available profile. The approach places Syntropic in a competitive field that includes established neurostimulation modalities such as transcranial magnetic stimulation and electroconvulsive therapy, as well as digital therapeutics and psychedelic-assisted treatment providers. Those are broad category comparisons rather than verified peer-company matches. Syntropic’s potential advantage is the combination of a wearable form factor, a specific 60 Hz mechanism, and an evidence-first development strategy spanning US and European programs. Its primary market-position risks remain clinical validation, regulatory clearance, treatment durability, and reimbursement.

Syntropic Medical has progressed from formation in August 2023 to a four-round capital history totaling $2.59 million. The initial $1.19 million pre-seed round on Apr 4, 2024 provided backing from XISTA Science Ventures and Austria Wirtschaftsservice (aws). A further $871,122 grant from the Austrian Research Promotion Agency (FFG) followed on Jul 22, 2024, supporting the company’s research and development base. The company then reported a $524,104 seed round on Mar 1, 2025 and a later venture round led by better ventures on Dec 4, 2025, with no disclosed amount. The sequence indicates continued financing through early product and clinical-development stages rather than a transition to large-scale commercialization. Product development is centered on Haven™, a headset using 60 Hz visual neuromodulation for rapid neuroplasticity therapy in Major Depressive Disorder, with possible future applications in PTSD, anxiety, and sleep. Four current team positions span executive leadership, technology, research, and founding roles. The main inflection points ahead are clinical evidence generation, regulatory pathway execution, and conversion of the device from an investigational therapy into an adopted treatment.